Login / Signup

Discovery of a Novel Series of Potent SHP2 Allosteric Inhibitors.

Alessia PetrocchiAlessandro GrilloLuca FerrantePietro RandazzoAdolfo PrandiMarilenia De MatteoCostanza IaccarinoMonica BisbocciAntonella CellucciCristina AlliMartina NibbioVincenzo PucciJérôme AmaudrutChristian MontalbettiCarlo ToniattiRomano Di Fabio
Published in: ACS medicinal chemistry letters (2023)
Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is the first reported nonreceptor oncogenic tyrosine phosphatase connecting multiple signal transduction cascades and exerting immunoinhibitory function through the PD-1 checkpoint receptor. As part of a drug discovery program aimed at obtaining novel allosteric SHP2 inhibitors, a series of pyrazopyrazine derivatives bearing an original bicyclo[3.1.0]hexane basic moiety on the left-hand side region of the molecule were identified. We report herein the discovery process, the in vitro pharmacological profile, and the early developability features of compound 25 , one of the most potent members of the series.
Keyphrases
  • small molecule
  • drug discovery
  • protein protein
  • cell cycle
  • tyrosine kinase
  • protein kinase
  • binding protein
  • anti inflammatory
  • cell proliferation